Your browser doesn't support javascript.
Hyperimmune globulin for severely immunocompromised patients hospitalized with COVID-19: a randomized, controlled trial.
Huygens, Sammy; Hofsink, Quincy; Nijhof, Inger S; Goorhuis, Abraham; Kater, Arnon P; Te Boekhorst, Peter Aw; Swaneveld, Francis; Novotný, Vera Mj; Bogers, Susanne; Welkers, Matthijs Ra; Papageorgiou, Grigorios; Rijnders, Bart J; Heijmans, Jarom.
  • Huygens S; Department of Internal Medicine, Section of Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Hofsink Q; Department of Hematology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Nijhof IS; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Goorhuis A; Department of Internal Medicine-Hematology, St. Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
  • Kater AP; Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Te Boekhorst PA; Department of Hematology, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Swaneveld F; Department of Hematology, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Novotný VM; Unit of Transfusion Medicine, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands.
  • Bogers S; Unit of Transfusion Medicine, Sanquin Blood Supply Foundation, 1066 CX Amsterdam, The Netherlands.
  • Welkers MR; Department of Viroscience, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Papageorgiou G; Department of Medical Microbiology & Infection Prevention, Amsterdam UMC location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  • Rijnders BJ; Department of Biostatistics, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
  • Heijmans J; Department of Internal Medicine, Section of Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
J Infect Dis ; 2022 Aug 04.
Article in English | MEDLINE | ID: covidwho-2241627
ABSTRACT
The aim of this randomized, controlled trial is to determine whether anti-SARS-CoV-2 hyperimmune globulin protects against severe COVID-19 in severely immunocompromised, hospitalized, COVID-19 patients. Patients were randomly assigned to receive anti-SARS-CoV-2 hyperimmune globulin (COVIG) or intravenous immunoglobulin without SARS-CoV-2 antibodies. Severe COVID-19 was observed in two out of ten (20%) patients treated with COVIG compared to seven out of eight (88%) in the IVIG control group (p = 0.015, Fisher's exact test). COVIG may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available. The trial was registered at www.trialregister.nl (#NL9436).
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Infdis